247 related articles for article (PubMed ID: 32694900)
21. The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China.
Wang X; Wang L; Yu Q; Liu Z; Li C; Wang F; Yu Z
Technol Cancer Res Treat; 2021; 20():15330338211037812. PubMed ID: 34342244
[TBL] [Abstract][Full Text] [Related]
22. Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study.
Li F; Xu F; Li J; Wang T; Bian L; Zhang S; Jiang Z
Ann Transl Med; 2021 Jan; 9(2):103. PubMed ID: 33569405
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Takano T; Tsurutani J; Takahashi M; Yamanaka T; Sakai K; Ito Y; Fukuoka J; Kimura H; Kawabata H; Tamura K; Matsumoto K; Aogi K; Sato K; Nishio K; Nakagawa K; Saeki T
Breast; 2018 Aug; 40():67-75. PubMed ID: 29698927
[TBL] [Abstract][Full Text] [Related]
24. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
[TBL] [Abstract][Full Text] [Related]
25. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T
Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.
Li C; Bian X; Liu Z; Wang X; Song X; Zhao W; Liu Y; Yu Z
Cancer Med; 2021 Dec; 10(23):8352-8364. PubMed ID: 34672424
[TBL] [Abstract][Full Text] [Related]
27. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).
Baez-Vallecillo L; Raghavendra AS; Hess KR; Barcenas CH; Moulder SL; Tripathy D; Valero V; Murthy RK
Breast Cancer Res Treat; 2019 Jul; 176(1):227-234. PubMed ID: 30977027
[TBL] [Abstract][Full Text] [Related]
28. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
[TBL] [Abstract][Full Text] [Related]
29. Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.
Sun Y; Chen B; Li J; Peng L; Li S; Yu X; Li L
Cancer Manag Res; 2021; 13():7165-7174. PubMed ID: 34548820
[TBL] [Abstract][Full Text] [Related]
30. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo H; Sledge G; Koehler M; Ellis C; Casey M; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2010 Mar; 28(7):1124-30. PubMed ID: 20124187
[TBL] [Abstract][Full Text] [Related]
31. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
32. Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).
Qin S; Ji J; Xu RH; Wang W; Tang Y; Bi F; Li J; Wang K; Xu JM; Fan Q; Su W; Shen L
Oncologist; 2021 Sep; 26(9):e1567-e1580. PubMed ID: 34003545
[TBL] [Abstract][Full Text] [Related]
33. Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.
Hammerman A; Greenberg-Dotan S; Feldhamer I; Bitterman H; Yerushalmi R
PLoS One; 2015; 10(9):e0138229. PubMed ID: 26375590
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab plus pertuzumab in combination with chemotherapy in metastatic HER2-positive breast cancer: a retrospective single-armed cohort study in China.
Qian Y; Peng Y; Zhou H; Zhang L; Yuan Y
Ann Transl Med; 2022 Aug; 10(16):877. PubMed ID: 36111041
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.
Yin S; Chi Y; Du Y; Wang J; Shan C; Yi W; Shang M; Man X; Tan Q; Li H
Cancer Med; 2023 Feb; 12(3):2333-2344. PubMed ID: 35894763
[TBL] [Abstract][Full Text] [Related]
36. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
38. Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
Li J; Wang S; Wang Y; Wang X; Wang H; Feng J; Zhang Q; Sun T; Ouyang Q; Yin Y; Liu Y; Geng C; Yan M; Jiang Z
Oncologist; 2017 Nov; 22(11):1333-1338. PubMed ID: 28798274
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
Kawalec P; Łopuch S; Mikrut A
Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
[TBL] [Abstract][Full Text] [Related]
40. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
Montemurro F; Prat A; Rossi V; Valabrega G; Sperinde J; Peraldo-Neia C; Donadio M; Galván P; Sapino A; Aglietta M; Baselga J; Scaltriti M
Mol Oncol; 2014 Feb; 8(1):20-6. PubMed ID: 24075779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
